Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy

Tetrahydrocannabinols (THCs) antagonize the CB1 and CB2 cannabinoid receptors, whose signaling to the endocannabinoid system is essential for controlling cell survival and proliferation as well as psychoactive effects. Most tumor cells express a much higher level of CB1 and CB2; THCs have been investigated as potential cancer therapeutic due to their cannabimimetic properties. To date, THCs have been prescribed as palliative medicine to cancer patients but not as an anticancer modality. Growing evidence of preclinical research demonstrates that THCs reduce tumor progression by stimulating apoptosis and autophagy and inhibiting two significant hallmarks of cancer pathogenesis: metastasis and angiogenesis. However, the degree of their anticancer effects depends on the origin of the tumor site, the expression of cannabinoid receptors on tumor cells, and the dosages and types of THC. This review summarizes the current state of knowledge on the molecular processes that THCs target for their anticancer effects. It also emphasizes the substantial knowledge gaps that should be of concern in future studies. We also discuss the therapeutic effects of THCs and the problems that will need to be addressed in the future. Clarifying unanswered queries is a prerequisite to translating the THCs into an effective anticancer regime.

Automated summary

Tetrahydrocannabinols (THCs) have been investigated for their potential therapeutic effects in cancer due to their cannabimimetic properties. These compounds antagonize the CB1 and CB2 cannabinoid receptors, which are essential for controlling cell survival and proliferation. Preclinical research has shown that THCs reduce tumor progression by stimulating apoptosis and autophagy and inhibiting metastasis and angiogenesis. However, the efficacy of THCs as anticancer agents depends on various factors, such as the tumor origin, expression of cannabinoid receptors, and dosage and type of THC.